On April 25, 2022, Mithril Capital Management LLC mailed to Adagio Therapeutics, Inc. a supplement to the notice, notifying the Company that Mithril Capital additionally intended to introduce at the 2022 annual meeting an advisory, non-binding resolution that the Board be declassified in advance of the 2023 annual meeting of stockholders, so that all directors are subject to a stockholder vote on an annual basis. Also on April 25, 2022, Mithril Capital and the participating stockholders reached an agreement, memorialized in an email dated April 25, 2022, pursuant to which they agreed to vote all of their respective shares of common stock in favor of such declassification proposal.